Gene therapy: light is finally in the tunnel  

作　　者：Huibi Cao Robert S.Molday Jim Hu 

机构地区：[1]Programme in Physiology and Experimental Medicine,Hospital for Sick Children,Departments of Laboratory Medicine and Pathobiology,and Paediatrics,University of Toronto,Toronto,Ontario M5G,1X8,Canada [2]Department of Biochemistry and Molecular Biology,2350 Health Sciences Mall,University of British Columbia,Vancouver,B.C.V6T 1Z3,Canada

出　　处：《Protein & Cell》2011年第12期973-989,共17页蛋白质与细胞（英文版）

基　　金：Research in our laboratories was supported by Operating Grants from the Canadian Institutes of Health Research,the Canadian Cystic Fibrosis Foundation,and the Foundation Fighting Blindness-Canada.

摘　　要：After two decades of ups and downs,gene therapy has recently achieved a milestone in treating patients with Leber’s congenital amaurosis(LCA).LCA is a group of inherited blinding diseases with retinal degeneration and severe vision loss in early infancy.Mutations in several genes,including RPE65,cause the disease.Using adenoassociated virus as a vector,three independent teams of investigators have recently shown that RPE65 can be delivered to retinal pigment epithelial cells of LCA patients by subretinal injections resulting in clinical benefits without side effects.However,considering the whole field of gene therapy,there are still major obstacles to clinical applications for other diseases.These obstacles include innate and immune barriers to vector delivery,toxicity of vectors and the lack of sustained therapeutic gene expression.Therefore,new strategies are needed to overcome these hurdles for achieving safe and effective gene therapy.In this article,we shall review the major advancements over the past two decades and,using lung gene therapy as an example,discuss the current obstacles and possible solutions to provide a roadmap for future gene therapy research.

关 键 词：gene therapy TRANSGENES viral vector non-viral vector helper-dependent adenoviral vector adenoassociated virus LENTIVIRUS cystic fibrosis transmembrane conductance regulator(CFTR) host immune responses 

分 类 号：R73[医药卫生—肿瘤]